RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

23 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

23 июл 2024 07:30:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 июл 2024 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

08 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

28 июн 2024 08:00:14 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 июн 2024 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

03 июн 2024 16:02:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

03 июн 2024 08:02:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

22 май 2024 04:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

09 май 2024 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

07 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

06 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

29 апр 2024 18:30:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

24 апр 2024 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 апр 2024 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

01 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

25 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

06 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

22 фев 2024 07:01:00 Источник Nasdaq GlobeNewswire